New evidence has demonstrated that IR and chemotherapy activate Type I IFN signalling in tumour and host cells, and IR stimulates the binding of cytoplasmic DDX58 to small endogenous noncoding RNAs (sncRNAs), thereby activating the Type I IFN signalling pathway (27). Here, RIGI is linked to neoplasm.